Tasigna (Nilotinib) is a targeted therapy used in the treatment of certain types of leukemia, especially Chronic Myeloid Leukemia (CML). It works by specifically targeting cancer cells to help control disease progression.
What is Tasigna (Nilotinib)?
Tasigna belongs to a class of drugs known as Tyrosine Kinase Inhibitors (TKIs). It targets the BCR-ABL protein responsible for abnormal cancer cell growth in CML.
In Chronic Myeloid Leukemia, this protein causes uncontrolled production of abnormal blood cells. Tasigna works by:
- Blocking cancer cell growth signals
- Reducing abnormal blood cell proliferation
- Helping control disease progression
In simple terms:
It targets the molecular cause behind leukemia cell growth.
Indications
Tasigna (Nilotinib) is used in:
- Chronic Myeloid Leukemia (CML)
- Philadelphia chromosome-positive (Ph+) leukemia cases
Dosage and Administration
- Dose depends on the condition and treatment protocol
- Taken orally
- Usually twice daily
- Should be taken consistently at the same times every day
- Preferably taken away from food according to physician instructions
Common Side Effects
May include:
- Headache
- Nausea
- Skin rash
- Fatigue
- Muscle pain
- Liver function abnormalities
Rarely: heart-related side effects requiring close monitoring.
Monitoring During Treatment
Patients on Tasigna (Nilotinib) require:
- Complete blood count monitoring
- Liver function tests
- ECG monitoring
- Evaluation of treatment response
Availability & How to Access Treatment
Tasigna (Nilotinib) is available through Macrocare’s approved partners.
You can now request and access the medication easily through us.
WhatsApp contact for medication requests:
Click here
Tasigna (Nilotinib) Tasigna (Nilotinib) 150 mg is an effective targeted therapy for CML that works by blocking abnormal leukemia cell growth and improving disease control.
Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.